Ceftobiprole

Background

Mechanism of Action

• Binds to and inhibits PBP-2a on MRSA
• Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae

Spectrum of Activity

• Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
• Not active against Pseudomonas, ESBL-producers, or AmpC-producers

Pharmacokinetics and Pharmacodynamics

• Crosses into CSF adequately

Dosing

• Ceftobiprole 500 mg IV q8h over 2 hours

Renal Dosing

• Required if CrCl <50 mL/min

Safety

Adverse Drug Reactions

• Nausea, diarrhea, neutropenia (4%), dysgeusia